Skip to content

ProViS (Prolift+M and Vita Sexualis) Study

ProViS (Prolift+M TM and Vita Sexualis) Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01997996
Acronym
ProViS
Enrollment
18
Registered
2013-11-28
Start date
2011-05-31
Completion date
2013-10-31
Last updated
2013-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pelvic Organ Prolapse

Keywords

Pelvic Organ Prolapse, PROLIFT+M, Vita sexualis

Brief summary

Transvaginal meshes (TVM) are indicated for the treatment of pelvic organ prolapse (POP) where surgical intervention is necessary. Due to a potential risk of de novo dyspareunia, TVM are mainly used in postmenopausal women and in case of recurrent POP. PROLIFT+M (Trademark) is based on a highly flexible material which is partially absorbable. We suggest that PROLIFT+M has less impact on the vita sexualis than conventional TVM and could also be used for the treatment of younger and/or sexually active women. This study observes women who are routinely treated with PROLIFT+M with regard to their sexual function before and after the surgery. The hypothesis is that there is no worsening in vita sexualis with PROLIFT+M.

Interventions

None listed

Sponsors

Dr. med. Tanja Hülder
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient understands the nature and content of the trial * POP ≥ stage II (according to the POP-Q system (18)) * Sexual intercourse ≥ 2x/4 weeks * Written informed consent * Negative pregnancy test in women of childbearing potential * Women ≥ 18 years

Exclusion criteria

* Concomitant surgery at the inner genitalis (e.g. colporrhaphy, sacrocolpopexy, sacrospinous fixation, hysterectomy); concomitant suburethral slings and bulking agents are allowed * Unable to read or speak German * Women \< 18 years * Women who are pregnant or breastfeeding or planning future pregnancies * Acute infection(s), e.g. untreated urogenital infections

Design outcomes

Primary

MeasureTime frameDescription
vita sexualis7 to 1 day Preoperative vs. 12 months (+/- 1 month) PostoperativeNo worsening in vita sexualis (decrease in total score Female Sexual Function Index (FSFI-d) of ≤ 3.3; max. score = 36) measured at 12 months (+/- 1 month) postoperatively as compared to the preoperative score.

Secondary

MeasureTime frameDescription
pain during sexual intercourse7 to 1 day Preoperative vs. 12 months (+/- 1 month) PostoperativeNo worsening in pain during sexual intercourse (decrease in weighted pain subscore FSFI-d of ≤ 1; max score = 6) measured at 12 months (+/- 1 month) postoperatively compared to preoperative.
Assessment of pelvic floor function7 to 1 day Preoperative vs. 12 months (+/- 1 month) PostoperativeAssessment of pelvic floor function using the validated German pelvic floor questionnaire at 12 months (+/- 1 month) postoperatively compared to preoperative (Deutscher Beckenboden-Fragebogen, validated German Version of the Australian Pelvic Floor Questionnaire
Assessment of patient satisfaction12 months (+/- 1 month) PostoperativeAssessment of patient satisfaction at 12 months (+/- 1 month) postoperatively using the visual analogue scale (VAS), question regarding reoperation and patient global (PGI) question.VAS: On top of two scales, the question How satisfied are you with the result of your operation? is placed. (Facial expressions are put above the line to express satisfaction visually). In addition, the following two questions are asked: Would you have the operation done again? and In the past 12 months how would you rate your condition as opposed to before your recent pelvic floor operation: much better/a little better/about the same/a little worse/much worse (PGI question).
Assessment of recurrent POP (POP-Q ≥ stage II)3 months (12 weeks +/- 2) and 12 months (+/- 1 month) postoperativelyAssessment of recurrent POP (POP-Q ≥ stage II in the operated compartment(s)), mesh erosion/exposure; each measured 3 (12 +/- 2 weeks) and 12 months (+/- 1 month) postoperatively by clinical examination (Speculum, palpation, POP-Q)
Safetyuntil 12 months (+/- 1 month) postoperativelySafety (documentation and assessment of medical device incidents; serious incidents and near incidents will be reported to the competent authorities)

Countries

Germany, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026